Clinical trial · Interventional
The Affect of Hemostasis Technique During Laparoscopic Ovarian Cystectomy on Future Fertility
The Affect of Hemostasis With Bipolar Coagulation Versus SURGIFLO Placement on Ovarian Reserve and Future Fertility
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients undergoing elective laparoscopic ovarian cystectomy will be recruited and randomly divided into 2 groups according to intervention technique-half will be allocated to the bipolar coagulation group and half to the SURGIFLO group. Patients will be assessed both pre-operatively and 6 months post-operatively by blood tests including follicle stimulating hormone (FSH), lutenizing hormone (LH), Estrogen (E2), Progesterone and anti-mullerian hormone (AMH) levels, and sonographic evaluation of ovarian volume and antral follicle count.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cyst Ovary | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bipolar coagulation forceps (ETHICON inc.) | Device | — | UNRESOLVED |
| SURGIFLO hemostatic matrix (ETHICON inc.) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Hemostasis with bipolar coagulation
- description
- Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
- interventionNames
- Device: Bipolar coagulation forceps (ETHICON inc.)
- type
- EXPERIMENTAL
- label
- Hemostasis with SURGIFLO
- description
- Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
- interventionNames
- Device: SURGIFLO hemostatic matrix (ETHICON inc.)
Primary outcomes (1)
- measure
- Decline in ovarian reserve.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 44 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with benign ovarian cysts that are interested in future fertility ages 18-44. Exclusion Criteria: * Female patients with malignant ovarian cysts/masses.
References
Publications (0)
Data not yet available